OBI Pharma, Inc. was informed by the patent office that patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions And Uses Thereof has been granted by United States Patent and Trademark Office under the patent number 15/662,162. OBI-866 is an active immunotherapeutic cancer vaccine targeting SSEA-4, conjugating SSEA-4 and carrier protein KLH and triggers immune responses against hard-to-treat cancers once injected into the human system. OBI-866 has been granted by TFDA to proceed to Phase I human clinical study and is now open for enrollment actively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
58.8 TWD | -0.51% | -1.67% | -15.27% |
1st Jan change | Capi. | |
---|---|---|
-15.27% | 416M | |
+45.96% | 56.69B | |
-2.96% | 41B | |
+38.65% | 38.11B | |
-11.22% | 26.89B | |
+15.15% | 25.59B | |
-21.93% | 18.59B | |
+0.06% | 12.39B | |
+25.75% | 11.99B | |
+22.10% | 11.88B |
- Stock Market
- Equities
- 4174 Stock
- News OBI Pharma, Inc.
- United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof